针对癌症中的 PI3K 信号通路。
Targeting the PI3K signaling pathway in cancer.
机构信息
Department of Medicine, Harvard Medical School, Boston, MA 02115, United States.
出版信息
Curr Opin Genet Dev. 2010 Feb;20(1):87-90. doi: 10.1016/j.gde.2009.11.002. Epub 2009 Dec 16.
Abstract
The phosphoinositide 3-kinase (PI3K) pathway is activated in a variety of different human cancers, and inhibitors of this pathway are under active development as anti-cancer therapeutics. In this review, we discuss the data supporting the use of PI3K pathway inhibitors in genetically and clinically defined cancers. This review focuses on their efficacy as single agents and in combination with other targeted therapies, specifically those targeting the MEK-ERK signaling pathway.
摘要
磷酸肌醇 3-激酶（PI3K）途径在多种不同的人类癌症中被激活，该途径的抑制剂作为抗癌治疗药物正在积极开发中。在这篇综述中，我们讨论了支持在遗传和临床定义的癌症中使用 PI3K 途径抑制剂的数据。这篇综述重点介绍了它们作为单一药物以及与其他靶向治疗（特别是针对 MEK-ERK 信号通路的靶向治疗）联合使用的疗效。
相似文献
1
Targeting the PI3K signaling pathway in cancer.
Curr Opin Genet Dev. 2010 Feb;20(1):87-90. doi: 10.1016/j.gde.2009.11.002. Epub 2009 Dec 16.
2
Targeting the PI3K signaling pathway in cancer therapy.
Expert Opin Ther Targets. 2012 Jan;16(1):121-30. doi: 10.1517/14728222.2011.644788. Epub 2012 Jan 12.
3
Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors.
Eur J Cancer. 2013 Dec;49(18):3936-44. doi: 10.1016/j.ejca.2013.08.007. Epub 2013 Sep 3.
4
Targeting PI3K/Akt signal transduction for cancer therapy.
Signal Transduct Target Ther. 2021 Dec 16;6(1):425. doi: 10.1038/s41392-021-00828-5.
5
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.
Oncotarget. 2012 Oct;3(10):1068-111. doi: 10.18632/oncotarget.659.
6
PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1.
Proc Natl Acad Sci U S A. 2013 Dec 24;110(52):21124-9. doi: 10.1073/pnas.1314124110. Epub 2013 Dec 10.
7
Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT.
Clin Cancer Res. 2014 Jul 1;20(13):3507-20. doi: 10.1158/1078-0432.CCR-13-2769. Epub 2014 May 30.
8
Targeting PI3K Signaling in Combination Cancer Therapy.
Trends Cancer. 2017 Jun;3(6):454-469. doi: 10.1016/j.trecan.2017.04.002. Epub 2017 May 14.
9
Optimal targeting of HER2-PI3K signaling in breast cancer: mechanistic insights and clinical implications.
Cancer Res. 2013 Jul 1;73(13):3817-20. doi: 10.1158/0008-5472.CAN-13-0687. Epub 2013 Jun 21.
10
Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.
J Hematol Oncol. 2020 Feb 22;13(1):13. doi: 10.1186/s13045-020-0846-y.
引用本文的文献
1
Metabolic reprogramming in hepatocellular carcinoma: mechanisms of immune evasion and therapeutic implications.
Front Immunol. 2025 Apr 30;16:1592837. doi: 10.3389/fimmu.2025.1592837. eCollection 2025.
2
Modulating phosphatase DUSP22 with BML-260 ameliorates skeletal muscle wasting via Akt independent JNK-FOXO3a repression.
EMBO Mol Med. 2025 Apr 22. doi: 10.1038/s44321-025-00234-2.
3
New job for an old tool: PI3Kβ phosphorylates OGT to regulate acetyl-CoA in glioblastoma.
Trends Cell Biol. 2025 May;35(5):361-363. doi: 10.1016/j.tcb.2025.04.002. Epub 2025 Apr 16.
4
Tumor suppressive effect of low-frequency repetitive transcranial magnetic stimulation on glioblastoma progression.
Neurotherapeutics. 2025 Jul;22(4):e00569. doi: 10.1016/j.neurot.2025.e00569. Epub 2025 Mar 27.
5
Synergistic Effects of the Combination of Alpelisib (PI3K Inhibitor) and Ribociclib (CDK4/6 Inhibitor) in Preclinical Colorectal Cancer Models.
Int J Mol Sci. 2024 Dec 10;25(24):13264. doi: 10.3390/ijms252413264.
6
MTHFD1 Regulates Autophagy to Promote Growth and Metastasis in Colorectal Cancer via the PI3K-AKT-mTOR Signaling Pathway.
Cancer Med. 2024 Nov;13(22):e70267. doi: 10.1002/cam4.70267.
7
How lactate affects immune strategies in lymphoma.
Front Mol Biosci. 2024 Oct 11;11:1480884. doi: 10.3389/fmolb.2024.1480884. eCollection 2024.
8
Competing endogenous RNAs regulatory crosstalk networks: The messages from the RNA world to signaling pathways directing cancer stem cell development.
Heliyon. 2024 Jul 26;10(15):e35208. doi: 10.1016/j.heliyon.2024.e35208. eCollection 2024 Aug 15.
9
TWEAK/Fn14 signalling driven super-enhancer reprogramming promotes pro-metastatic metabolic rewiring in triple-negative breast cancer.
Nat Commun. 2024 Jul 5;15(1):5638. doi: 10.1038/s41467-024-50071-z.
10
Inhibition of ABI2 ubiquitination-dependent degradation suppresses TNBC cell growth via down-regulating PI3K/Akt signaling pathway.
Cancer Cell Int. 2024 Jun 27;24(1):222. doi: 10.1186/s12935-024-03407-0.
本文引用的文献
1
Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition.
Proc Natl Acad Sci U S A. 2009 Nov 17;106(46):19503-8. doi: 10.1073/pnas.0905056106. Epub 2009 Oct 22.
2
Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer.
Proc Natl Acad Sci U S A. 2009 Oct 27;106(43):18351-6. doi: 10.1073/pnas.0907325106. Epub 2009 Oct 5.
3
Targeting PI3K signalling in cancer: opportunities, challenges and limitations.
Nat Rev Cancer. 2009 Aug;9(8):550-62. doi: 10.1038/nrc2664.
4
AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer.
Cancer Cell. 2009 Jul 7;16(1):21-32. doi: 10.1016/j.ccr.2009.04.012.
5
In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.
Clin Cancer Res. 2009 Jul 15;15(14):4649-64. doi: 10.1158/1078-0432.CCR-09-0317. Epub 2009 Jun 30.
6
Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.
Cancer Cell. 2009 May 5;15(5):429-40. doi: 10.1016/j.ccr.2009.03.020.
7
Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition.
Cancer Res. 2009 Jan 15;69(2):565-72. doi: 10.1158/0008-5472.CAN-08-3389.
8
Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance.
Cancer Res. 2009 Jan 1;69(1):143-50. doi: 10.1158/0008-5472.CAN-07-6656.
9
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.
Nat Med. 2008 Dec;14(12):1351-6. doi: 10.1038/nm.1890. Epub 2008 Nov 30.
10
NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.
Cancer Res. 2008 Oct 1;68(19):8022-30. doi: 10.1158/0008-5472.CAN-08-1385.
Zotero 插件